Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.84 -1.11%

-$0.04 today

Market cap
$698.58M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 3.99M

Average 2.47M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$162.56M

FY 2025 · Annual

Investing Cash Flow

-$108.76M

FY 2025 · Annual

Financing Cash Flow

$151.51M

FY 2025 · Annual

-22.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
Deferred Income Tax(624K)(964K)(279K)00
Stock-Based Compensation1.75M6.46M13.91M26.07M29.27M
Change in Working Capital31.18M(35.4M)2.65M31.08M(5.34M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.19M2.46M9.14M(5.26M)996K
Other Working Capital29.99M(37.86M)(6.49M)36.33M(6.34M)
Other Non-Cash Items98.42M17.68M11.79M9.75M9.27M
Operating Cash Flow(34.08M)(131.83M)(165.41M)(122.87M)(162.56M)
Capital Expenditures(4.15M)(16.1M)(8.72M)(7.29M)(4.53M)
Acquisitions (Net)00000
Purchases of Investments(81.98M)(123.34M)(104.95M)(129.45M)(205.41M)
Sales of Investments13M93M132.56M204.2M101.18M
Other Investing Activities(496K)(665K)(170K)1M0
Investing Cash Flow(73.63M)(47.1M)18.71M68.46M(108.76M)
Debt Repayment00000
Common Stock Issued270.36M185.32M655K170.14M139.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.09M)(3.82M)025.74M12M
Financing Cash Flow269.28M181.49M655K195.88M151.51M
Effect of Forex Changes00000
Net Change in Cash161.57M2.57M(146.05M)141.47M(119.82M)
Free Cash Flow(38.23M)(147.92M)(174.14M)(130.16M)(167.1M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$201.1M
+ D&A$5.4M
+ Stock-Based Comp$29.3M
+ Deferred Tax$0
- Working Capital-$5.3M
+ Other Non-Cash$9.3M
= Operating Cash Flow-$162.6M
- Capex-$4.5M
= Free Cash Flow-$167.1M

Analysis

FY2025 free cash flow is -$167.1M. FCF conversion is 83.1% of net income. Operating cash flow was -$162.6M, with capex of -$4.5M. The largest bridge item is Stock-Based Comp at $29.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingNov 13, 2026
SC 13GSC 13G filingNov 13, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
8-KCurrent reportNov 12, 2026

Does PRME generate free cash flow?

Prime Medicine, Inc. (PRME) generated -$167.09M of free cash flow in fiscal 2025.

How much operating cash flow does PRME produce?

Operating cash flow was -$162.56M, before capital expenditures of $4.53M.